公开(公告)号：EP4397317A3

公开(公告)日：2024-10-16

申请号：EP24170976.5

申请日：2018-08-30

申请人： Eli Lilly and Company

发明人： AURORA, Sheena ,  JOHNSON, Kirk Willis ,  KREGE, John Henry

IPC分类号： A61K31/4545 ,  A61P25/06 ,  A61K39/395 ,  A61K31/517

摘要： The present invention relates to combinations of lasmiditan and a calcitonin gene-related peptide (CGRP) antagonist such as rimegepant, ubrogepant, olcegepant, and MK-8031 and to methods of using the combinations for treatment of migraine, particularly migraine inadequately controlled by lasmiditan or a CGRP antagonist therapy alone, and more particularly, to treat therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment regimens.

公开(公告)号：EP4397317A2

公开(公告)日：2024-07-10

申请号：EP24170976.5

申请日：2018-08-30

申请人： Eli Lilly and Company

发明人： AURORA, Sheena ,  JOHNSON, Kirk Willis ,  KREGE, John Henry

IPC分类号： A61K39/395

CPC分类号： A61K31/4545 ,  A61P25/06 ,  A61K39/3955 ,  C07K16/18 ,  C07K2317/2420130101 ,  C07K2317/7620130101

摘要： The present invention relates to combinations of lasmiditan and a calcitonin gene-related peptide (CGRP) antagonist such as rimegepant, ubrogepant, olcegepant, and MK-8031 and to methods of using the combinations for treatment of migraine, particularly migraine inadequately controlled by lasmiditan or a CGRP antagonist therapy alone, and more particularly, to treat therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment regimens.

公开(公告)号：EP3678665A1

公开(公告)日：2020-07-15

申请号：EP18766557.5

申请日：2018-08-30

申请人： Eli Lilly and Company

发明人： AURORA, Sheena ,  JOHNSON, Kirk Willis ,  KREGE, John Henry

IPC分类号： A61K31/4545 ,  A61P25/06 ,  A61K39/395